InnoCare Pharma Limited
INCPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 36.7% | 18.1% | -40% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $0 | $1 |
| % Margin | 86.3% | 82.6% | 77.1% | 93.7% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$0 |
| % Margin | -52.1% | -88.2% | -123.2% | -17.4% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$1 | -$1 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$1 | -$0 |
| % Margin | -43.7% | -85.5% | -141.8% | -6.2% |
| EPS | -0.26 | -0.37 | -0.6 | -0.037 |
| % Growth | 29.7% | 38.3% | -1,539.3% | – |
| EPS Diluted | -0.26 | -0.37 | -0.6 | -0.037 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$0 |
| % Margin | -31% | -69.9% | -129.2% | -16% |